2022年度胰腺癌研究及诊疗新进展

doi:10.19401/j.cnki.1007-3639.2023.01.001

中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (1): 1-13.doi: 10.19401/j.cnki.1007-3639.2023.01.001

2022年度胰腺癌研究及诊疗新进展

王旭(), 程合, 刘辰, 虞先濬()

复旦大学附属肿瘤医院胰腺外科，复旦大学上海医学院肿瘤学系，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，上海 200032

收稿日期:2022-12-30 修回日期:2023-01-13 出版日期:2023-01-30 发布日期:2023-02-13
通信作者: 虞先濬（ORCID: 0000-0002-6697-7143），博士，教授、主任医师，复旦大学附属肿瘤医院副院长。
作者简介:王旭（ORCID: 0000-0001-6920-0375），博士，副研究员。
虞先濬，主任医师，二级教授，外科学和肿瘤学双科博士研究生导师，现任复旦大学附属肿瘤医院副院长、上海市胰腺肿瘤研究所所长、复旦大学胰腺肿瘤研究所所长、中国抗癌协会胰腺癌专业委员会主任委员。长期从事胰腺肿瘤外科基础和临床转化研究。获得国家杰出青年科学基金、全国五一劳动奖章，入选科技部“中青年科技创新领军人才”、国家百千万人才工程“有突出贡献中青年专家”，享受国务院政府特殊津贴，被评为上海市科技精英、上海市领军人才、上海工匠、上海市优秀学术带头人。主持国家自然科学基金中德国际重点合作项目1项、区域合作重点项目1项、面上项目3项，省部级项目12项。以通信作者在Journal of Clinical Oncology、Gut、Annals of Surgery、Cell Research、Autophagy、Clinical Cancer Research、Cancer Research等国际权威SCI收录期刊上发表论文200余篇，获得国家实用新型专利5项。作为第一完成人获得中国抗癌协会科技奖一等奖、上海医学科技奖一等奖、上海市职工优秀创新成果奖一等奖。
基金资助:
国家自然科学基金(82172884);国家自然科学基金(82072693);国家自然科学基金(81902417);国家自然科学基金(U21A20374);上海市教委科技创新项目(2019-01-07-00-07-E00057);上海市科技重大专项(21JC1401500);上海市医院发展中心临床与科技创新项目(SHDC12018109);上海市医院发展中心临床与科技创新项目(SHDC2020CR1006A);国家重点研发计划(2020YFA0803202)

New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022

WANG Xu(), CHENG He, LIU Chen, YU Xianjun()

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute, Shanghai 200032, China

Received:2022-12-30 Revised:2023-01-13 Published:2023-01-30 Online:2023-02-13
Contact: YU Xianjun

摘要/Abstract

摘要：

胰腺癌是中国致死人数排名第六的恶性肿瘤，其恶性程度高，早期病情隐匿，超过80%的患者在就诊时已进展为晚期，错失手术切除治愈的机会；而成功接受了手术治疗的胰腺癌患者，也极易发生转移，5年生存率仅为15% ~ 20%。不同于其他癌种，胰腺癌的放化疗及免疫治疗效率均较低，分子分型和精准治疗技术的研究也相对落后，急需临床医疗资源的投入和优质科研成果的转化，以改善患者预后。2022年是胰腺癌转化研究领域厚积薄发的一年，见证了第1个靶向KRAS^G12D的小分子药物的诞生和个性化T细胞受体工程化T（T-cell receptor engineered T，TCR-T）细胞治疗技术的临床应用，在胰腺癌发病因素、分子机制、代谢、免疫微环境等基础领域，以及早期诊断、手术治疗、药物治疗、免疫治疗等临床领域也各自取得了新突破。本文对2022年胰腺癌研究和诊疗领域的最新进展进行综述。

关键词: 胰腺癌, 基础研究, 临床研究

Abstract:

Pancreatic cancer is the sixth leading cause of cancer-related death in China. It is characterized by high malignancy and concealment at early stages. More than 80% of patients have progressed to advanced stages at the time of diagnosis, and missed the opportunity of surgical resection. Pancreatic cancer patients who have successfully received surgical resection are at a high risk of metastasis, and the 5-year survival rate is only 15%-20%. Unlike other types of cancer, radiotherapy, chemotherapy and immunotherapy do not work well for pancreatic cancer, and the research in molecular subtyping and precision medical therapy technology is also slow. It is an urgent need to devote more clinical medical resources and transfer high-quality scientific research achievements to improve the prognosis of patients. The year 2022 is a year of profound accumulation in the field of translational pancreatic cancer research, witnessing the generation of the first small-molecule drug targeting KRAS^G12D and the clinical application of personalized T-cell receptor engineered T (TCR-T) cell therapy, as well as other advances in basic fields such as pathogenesis, molecular mechanism, metabolic immune microenvironment, and clinical fields such as early diagnosis, surgical treatment, radiation therapy, chemotherapy and immunotherapy. Here we reviewed the latest progress in research, diagnosis and treatment of pancreatic cancer in 2022.

Key words: Pancreatic cancer, Basic research, Clinical research

中图分类号:

R735.9

王旭, 程合, 刘辰, 虞先濬. 2022年度胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2023, 33(1): 1-13.

WANG Xu, CHENG He, LIU Chen, YU Xianjun. New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022[J]. China Oncology, 2023, 33(1): 1-13.

参考文献 106

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	WILD C P, WEIDERPASS E, STEWART B W. World cancer report: cancer research for cancer prevention[M]. Lyon: IARC Publications, 2020.
[3]	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022. 72(1): 7-33. doi: 10.3322/caac.21708
[4]	XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
[5]	IRFAN A, FANG H A, AWAD S, et al. Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma?[J]. Am J Surg, 2022, 224(3): 955-958. doi: 10.1016/j.amjsurg.2022.04.004 pmid: 35430088
[6]	ARJANI S, SAINT-MAURICE P F, JULIÁN-SERRANO S, et al. Body mass index trajectories across the adult life course and pancreatic cancer risk[J]. JNCI Cancer Spectr, 2022, 6(6): pkac066. doi: 10.1093/jncics/pkac066
[7]	SHARMA S, TAPPER W J, COLLINS A, et al. Predicting pancreatic cancer in the UK biobank cohort using polygenic risk scores and diabetes mellitus[J]. Gastroenterology, 2022, 162(6): 1665-1674.e2. doi: 10.1053/j.gastro.2022.01.016
[8]	WANG L, SCOTT F I, BOURSI B, et al. Cost-effectiveness of a risk-tailored pancreatic cancer early detection strategy among patients with new-onset diabetes[J]. Clin Gastroenterol Hepatol, 2022, 20(9): 1997-2004.e7. doi: 10.1016/j.cgh.2021.10.037
[9]	JULIÁN-SERRANO S, REEDY J, ROBIEN K, et al. Adherence to 5 diet quality indices and pancreatic cancer risk in a large US prospective cohort[J]. Am J Epidemiol, 2022, 191(9): 1584-1600. doi: 10.1093/aje/kwac082
[10]	MUNIGALA S, SUBRAMANIAM D S, SUBRAMANIAM D P, et al. Incidence and risk of pancreatic cancer in patients with a new diagnosis of chronic pancreatitis[J]. Dig Dis Sci, 2022, 67(2): 708-715. doi: 10.1007/s10620-021-06886-7
[11]	MUNIGALA S, ALMASKEEN S, SUBRAMANIAM D S, et al. Acute pancreatitis recurrences augment long-term pancreatic cancer risk[J]. Am J Gastroenterol, 2022. [Online ahead of print]
[12]	MAHAJAN U M, OEHRLE B, SIRTL S, et al. Independent validation and assay standardization of improved metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis[J]. Gastroenterology, 2022, 163(5): 1407-1422. doi: 10.1053/j.gastro.2022.07.047 pmid: 35870514
[13]	CHEN W S, CHEN Q L, PARKER R A, et al. Risk prediction of pancreatic cancer in patients with abnormal morphologic findings related to chronic pancreatitis: a machine learning approach[J]. Gastro Hep Adv, 2022, 1(6): 1014-1026. doi: 10.1016/j.gastha.2022.06.008
[14]	POLLINI T, ADSAY V, CAPURSO G, et al. The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms[J]. Lancet Gastroenterol Hepatol, 2022, 7(12): 1141-1150. doi: 10.1016/S2468-1253(22)00235-7
[15]	HERNANDEZ S, PARRA E R, URAOKA N, et al. Diminished immune surveillance during histologic progression of intraductal papillary mucinous neoplasms offers a therapeutic opportunity for cancer interception[J]. Clin Cancer Res, 28(9): 1938-1947. doi: 10.1158/1078-0432.CCR-21-2585
[16]	LIFFERS S T, GODFREY L, FROHN L, et al. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype[J]. Gut, 2022: gutjnl-gu2021-326550.
[17]	FELIX K, HONDA K, NAGASHIMA K, et al. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms[J]. Int J Cancer, 2022, 150(5): 881-894. doi: 10.1002/ijc.33875
[18]	YAMAGUCHI A, TAZUMA S, TAMARU Y, et al. Long-standing diabetes mellitus increases concomitant pancreatic cancer risk in patients with intraductal papillary mucinous neoplasms[J]. BMC Gastroenterol, 2022, 22(1): 529. doi: 10.1186/s12876-022-02564-8 pmid: 36539713
[19]	PEDUZZI G, ARCHIBUGI L, KATZKE V, et al. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women[J]. Sci Rep, 2022, 12(1): 18100. doi: 10.1038/s41598-022-22973-9 pmid: 36302831
[20]	CAO L W, HUANG C, CUI ZHOU D, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma[J]. Cell, 2021, 184(19): 5031-5052.e26. doi: 10.1016/j.cell.2021.08.023 pmid: 34534465
[21]	LEIDNER R, SANJUAN SILVA N, HUANG H Y, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer[J]. N Engl J Med, 2022, 386(22): 2112-2119. doi: 10.1056/NEJMoa2119662
[22]	ASTIAZARAN-SYMONDS E, KIM J, HALEY J S, et al. A genome-first approach to estimate prevalence of germline pathogenic variants and risk of pancreatic cancer in select cancer susceptibility genes[J]. Cancers, 2022, 14(13): 3257. doi: 10.3390/cancers14133257
[23]	GARDINER A, KIDD J, ELIAS M C, et al. Pancreatic ductal carcinoma risk associated with hereditary cancer-risk genes[J]. J Natl Cancer Inst, 2022, 114(7): 996-1002. doi: 10.1093/jnci/djac069
[24]	GIACCHERINI M, FARINELLA R, GENTILUOMO M, et al. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk[J]. Int J Cancer, 2022. [Online ahead of print]
[25]	SARDARZADEH N, KHOJASTEH-LEYLAKOOHI F, DAMAVANDI S, et al. Association of a genetic variant in the cyclin-dependent kinase inhibitor 2B with risk of pancreatic cancer[J]. Rep Biochem Mol Biol, 2022, 11(2): 336-343.
[26]	GIACCHERINI M, GENTILUOMO M, ARCIDIACONO P G, et al. A polymorphic variant in telomere maintenance is associated with worrisome features and high-risk stigmata development in IPMNs[J]. Carcinogenesis, 2022, 43(8): 728-735. doi: 10.1093/carcin/bgac051 pmid: 35675759
[27]	RAMAKRISHNAN G, PARAJULI P, SINGH P, et al. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma[J]. Cell Rep, 2022, 41(6): 111623. doi: 10.1016/j.celrep.2022.111623
[28]	TIAN J B, CHEN C, RAO M L, et al. Aberrant RNA splicing is a primary link between genetic variation and pancreatic cancer risk[J]. Cancer Res, 2022, 82(11): 2084-2096. doi: 10.1158/0008-5472.CAN-21-4367 pmid: 35363263
[29]	OZTURK H, CINGOZ H, TUFAN T R, et al. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer[J]. Dev Cell, 2022, 57(11): 1331-1346.e9. doi: 10.1016/j.devcel.2022.04.014 pmid: 35508175
[30]	HUANG H, PAN R N, ZHAO Y, et al. L3MBTL2-mediated CGA transcriptional suppression promotes pancreatic cancer progression through modulating autophagy[J]. iScience, 2022, 25(5): 104249. doi: 10.1016/j.isci.2022.104249
[31]	NI Q Z, ZHU B, JI Y, et al. PPDPF promotes the development of mutant KRAS-driven pancreatic ductal adenocarcinoma by regulating the GEF activity of SOS1[J]. Adv Sci (Weinh), 2022: e2202448.
[32]	DE ANDRÉS M P, JACKSON R J, FELIPE I, et al. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma[J]. Gut, 2022: gutjnl-gu2021-325803.
[33]	HE D, FENG H J, SUNDBERG B, et al. Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis[J]. Mol Cell, 2022, 82(16): 3045-3060.e11. doi: 10.1016/j.molcel.2022.06.005 pmid: 35752173
[34]	DOFFO J, BAMOPOULOS S A, KÖSE H, et al. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer[J]. Proc Natl Acad Sci U S A, 2022, 119(9): e2105691119.
[35]	CHENG R J, LI F Y, ZHANG M L, et al. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers[J]. Cell Res, 2022. [Online ahead of print]
[36]	MARUI S, NISHIKAWA Y, SHIOKAWA M, et al. Context-dependent roles of Hes1 in the adult pancreas and pancreatic tumor formation[J]. Gastroenterology, 2022, 163(6): 1613-1629.e12. doi: 10.1053/j.gastro.2022.08.048
[37]	FAN X Y, LU P, WANG H W, et al. Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma[J]. Cell Discov, 2022, 8(1): 13. doi: 10.1038/s41421-021-00366-y pmid: 35165277
[38]	SHI X H, LI Y G, YUAN Q Y, et al. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity[J]. Nat Commun, 2022, 13(1): 2169. doi: 10.1038/s41467-022-29857-6 pmid: 35449156
[39]	ZHU Q, ZHOU H, WU L M, et al. O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1[J]. Nat Chem Biol, 2022, 18(10): 1087-1095. doi: 10.1038/s41589-022-01085-5 pmid: 35879546
[40]	LIU Y, DEGUCHI Y, WEI D Y, et al. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ[J]. Nat Commun, 2022, 13(1): 2665. doi: 10.1038/s41467-022-30392-7
[41]	KONG W J, LIU Z S, SUN M N, et al. Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma[J]. Cancer Lett, 2022, 539: 215718. doi: 10.1016/j.canlet.2022.215718
[42]	GRECO B, MALACARNE V, DE GIRARDI F, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies[J]. Sci Transl Med, 2022, 14(628): eabg3072. doi: 10.1126/scitranslmed.abg3072
[43]	WANG Z K, MORESCO P, YAN R, et al. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack[J]. Proc Natl Acad Sci USA, 2022, 119(4): e2119463119.
[44]	MI H Y, SIVAGNANAM S, BETTS C B, et al. Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers[J]. Cancer Res, 2022, 82(23): 4359-4372. doi: 10.1158/0008-5472.CAN-22-1190
[45]	ZHOU D C, JAYASINGHE R G, CHEN S Q, et al. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer[J]. Nat Genet, 2022, 54(9): 1390-1405. doi: 10.1038/s41588-022-01157-1 pmid: 35995947
[46]	HUANG H C, WANG Z N, ZHANG Y Q, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer[J]. Cancer Cell, 2022, 40(6): 656-673.e7. doi: 10.1016/j.ccell.2022.04.011
[47]	KARTAL E, SCHMIDT T S B, MOLINA-MONTES E, et al. A faecal microbiota signature with high specificity for pancreatic cancer[J]. Gut, 2022, 71(7): 1359-1372. doi: 10.1136/gutjnl-2021-324755 pmid: 35260444
[48]	NAGATA N, NISHIJIMA S, KOJIMA Y, et al. Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study[J]. Gastroenterology, 2022, 163(1): 222-238. doi: 10.1053/j.gastro.2022.03.054 pmid: 35398347
[49]	GHADDAR B, BISWAS A, HARRIS C, et al. Tumor microbiome links cellular programs and immunity in pancreatic cancer[J]. Cancer Cell, 2022, 40(10): 1240-1253.e5. doi: 10.1016/j.ccell.2022.09.009 pmid: 36220074
[50]	SU H, YANG F, FU R, et al. Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome[J]. Nature, 2022, 610(7931): 366-372. doi: 10.1038/s41586-022-05169-z
[51]	HALBROOK C J, THURSTON G, BOYER S, et al. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells[J]. Nat Cancer, 2022, 3(11): 1386-1403. doi: 10.1038/s43018-022-00463-1
[52]	GUBBALA V B, JYTOSANA N, TRINH V Q, et al. Eicosanoids in the pancreatic tumor microenvironment-a multicellular, multifaceted progression[J]. Gastro Hep Adv, 2022, 1(4): 682-697.
[53]	KIM P K, HALBROOK C J, KERK S A, et al. Hyaluronic acid fuels pancreatic cancer cell growth[J]. Elife, 2021, 10: e62645. doi: 10.7554/eLife.62645
[54]	BAI J R, LIU T, TU B, et al. Autophagy loss impedes cancer-associated fibroblast activation via downregulating proline biosynthesis[J]. Autophagy, 2022: 1-12.
[55]	FALCOMATÀ C, BÄRTHEL S, WIDHOLZ S A, et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment[J]. Nat Cancer, 2022, 3(3): 318-336. doi: 10.1038/s43018-021-00326-1
[56]	GU J Y, HUANG W J, WANG X X, et al. Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemCitabine resistance in pancreatic cancer[J]. Mol Cancer, 2022, 21(1): 112. doi: 10.1186/s12943-022-01587-9 pmid: 35538494
[57]	LIU J J, JING W H, WANG T Y, et al. Functional metabolomics revealed the dual-activation of cAMP-AMP axis is a novel therapeutic target of pancreatic cancer[J]. Pharmacol Res, 2022, 187: 106554. doi: 10.1016/j.phrs.2022.106554
[58]	ZENG X Y, ZHAO F, CUI G F, et al. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma[J]. Nat Cancer, 2022, 3(9): 1088-1104. doi: 10.1038/s43018-022-00429-3
[59]	VAZIRI-GOHAR A, CASSEL J, MOHAMMED F S, et al. Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors[J]. Nat Cancer, 2022, 3(7): 852-865. doi: 10.1038/s43018-022-00393-y
[60]	WANG P Y, ZHANG T, WANG X J, et al. Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma[J]. Cell Chem Biol, 2022, 29(9): 1396-1408.e8. doi: 10.1016/j.chembiol.2022.07.002
[61]	LI J H, LAMA R, GALSTER S L, et al. Small-molecule MMRi62 induces ferroptosis and inhibits metastasis in pancreatic cancer via degradation of ferritin heavy chain and mutant p53[J]. Mol Cancer Ther, 2022, 21(4): 535-545. doi: 10.1158/1535-7163.MCT-21-0728
[62]	WENG N N, QIN S Y, LIU J Y, et al. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma[J]. Acta Pharm Sin B, 2022, 12(7): 3085-3102. doi: 10.1016/j.apsb.2022.01.018 pmid: 35865101
[63]	DA SILVA L, JIANG J M, PERKINS C, et al. Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia[J]. Cell Death Discov, 2022, 8(1): 378. doi: 10.1038/s41420-022-01165-4 pmid: 36055991
[64]	LAN L X, EVAN T, LI H F, et al. GREM1 is required to maintain cellular heterogeneity in pancreatic cancer[J]. Nature, 2022, 607(7917): 163-168. doi: 10.1038/s41586-022-04888-7
[65]	YUAN F, SUN M N, LIU Z S, et al. Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer[J]. Theranostics, 2022, 12(3): 1061-1073. doi: 10.7150/thno.65299 pmid: 35154474
[66]	CHEN Q J, WANG Q B, WANG Y, et al. Penetrating micelle for reversing immunosuppression and drug resistance in pancreatic cancer treatment[J]. Small, 2022, 18(18): e2107712.
[67]	TIBILETTI M G, CARNEVALI I, PENSOTTI V, et al. OncoPan®: an NGS-based screening methodology to identify molecular markers for therapy and risk assessment in pancreatic ductal adenocarcinoma[J]. Biomedicines, 2022, 10(5): 1208. doi: 10.3390/biomedicines10051208
[68]	KHAN S, LUCK H, WINER S, et al. Emerging concepts in intestinal immune control of obesity-related metabolic disease[J]. Nat Commun, 2021, 12(1): 2598. doi: 10.1038/s41467-021-22727-7 pmid: 33972511
[69]	PREVENTIVE SERVICES TASK FORCE U S, OWENS D K, DAVIDSON K W, et al. Screening for pancreatic cancer: US preventive services task force reaffirmation recommendation statement[J]. JAMA, 2019, 322(5): 438-444. doi: 10.1001/jama.2019.10232 pmid: 31386141
[70]	GOGGINS M, OVERBEEK K A, BRAND R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium[J]. Gut, 2020, 69(1): 7-17. doi: 10.1136/gutjnl-2019-319352 pmid: 31672839
[71]	HUANG C C, SIMEONE D M, LUK L, et al. Standardization of MRI screening and reporting in individuals with elevated risk of pancreatic ductal adenocarcinoma: consensus statement of the PRECEDE consortium[J]. AJR Am J Roentgenol, 2022, 219(6): 903-914. doi: 10.2214/AJR.22.27859
[72]	OVERBEEK K A, LEVINK I J M, KOOPMANN B D M, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals[J]. Gut, 2022, 71(6): 1152-1160. doi: 10.1136/gutjnl-2020-323611
[73]	QURESHI T A, JAVED S, SARMADI T, et al. Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review[J]. Chin Clin Oncol, 2022, 11(1): 1. doi: 10.21037/cco-21-117 pmid: 35144387
[74]	JAVED S, QURESHI T A, GADDAM S, et al. Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images[J]. Front Oncol, 2022, 12: 1007990. doi: 10.3389/fonc.2022.1007990
[75]	AHMAD QURESHI T, GADDAM S, WACHSMAN A M, et al. Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images[J]. Cancer Biomark, 2022, 33(2): 211-217. doi: 10.3233/CBM-210273 pmid: 35213359
[76]	LEVINK I J M, KLATTE D C F, HANNA-SAWIRES R G, et al. Longitudinal changes of serum protein N-glycan levels for earlier detection of pancreatic cancer in high-risk individuals[J]. Pancreatology, 2022, 22(4): 497-506. doi: 10.1016/j.pan.2022.03.021
[77]	DA PAIXÃO V F, SOSA O J, DA SILVA PELLEGRINA D V, et al. Annotation and functional characterization of long noncoding RNAs deregulated in pancreatic adenocarcinoma[J]. Cell Oncol, 2022, 45(3): 479-504. doi: 10.1007/s13402-022-00678-5
[78]	KANDIMALLA R, SHIMURA T, MALLIK S, et al. Identification of serum miRNA signature and establishment of a nomogram for risk stratification in patients with pancreatic ductal adenocarcinoma[J]. Ann Surg, 2022, 275(1): e229-e237. doi: 10.1097/SLA.0000000000003945
[79]	KONNO M, KOSEKI J, ASAI A, et al. Distinct methylation levels of mature microRNAs in gastrointestinal cancers[J]. Nat Commun, 2019, 10(1): 3888. doi: 10.1038/s41467-019-11826-1 pmid: 31467274
[80]	COUTO N, ELZANOWSKA J, MAIA J, et al. IgG + extracellular vesicles measure therapeutic response in advanced pancreatic cancer[J]. Cells, 2022, 11(18): 2800. doi: 10.3390/cells11182800
[81]	BHANDARE M S, PARRAY A, CHAUDHARI V A, et al. Minimally invasive surgery for pancreatic cancer-are we there yet? A narrative review[J]. Chin Clin Oncol, 2022, 11(1): 3. doi: 10.21037/cco-21-131
[82]	TOPAL H, AERTS R, LAENEN A, et al. Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma[J]. JAMA Netw Open, 2022, 5(12): e2248147. doi: 10.1001/jamanetworkopen.2022.48147
[83]	SUTTON T L, POTTER K C, MAYO S C, et al. Complications in distal pancreatectomy versus radical antegrade modular pancreatosplenectomy: a disease risk score analysis utilizing national surgical quality improvement project data[J]. World J Surg, 2022, 46(7): 1768-1775. doi: 10.1007/s00268-022-06545-6 pmid: 35403874
[84]	LI B, GUO S W, YIN X Y, et al. Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upfront surgery[J]. Asian J Surg, 2022: S1015-S9584(22)01438-5.
[85]	HACKERT T, KLAIBER U, HINZ U, et al. Portal vein resection in pancreatic cancer surgery: risk of thrombosis and radicality determine survival[J]. Ann Surg, 2022. [Online ahead of print]
[86]	ZHOU Y P, WANG J T, ZHANG S L, et al. A CT radiomics-based risk score for preoperative estimation of intraoperative superior mesenteric-portal vein involvement in pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2022. [Online ahead of print]
[87]	SAHLSTRÖM E, BEREZA-CARLSON P, NILSSON J, et al. Risk factors and outcomes for patients with pancreatic cancer undergoing surgical exploration without resection due to metastatic disease: a national cohort study[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(3): 279-284. doi: 10.1016/j.hbpd.2022.02.003
[88]	ZAMBIRINIS C P, MIDYA A, CHAKRABORTY J, et al. Recurrence after resection of pancreatic cancer: can radiomics predict patients at greatest risk of liver metastasis?[J]. Ann Surg Oncol, 2022, 29(8): 4962-4974. doi: 10.1245/s10434-022-11579-0 pmid: 35366706
[89]	ASAKURA Y, TOYAMA H, ISHIDA J, et al. Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma[J]. Asian J Surg, 2023, 46(1): 207-212. doi: 10.1016/j.asjsur.2022.03.043
[90]	PADRÓN L J, MAURER D M, O'HARA M H, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial[J]. Nat Med, 2022, 28(6): 1167-1177. doi: 10.1038/s41591-022-01829-9 pmid: 35662283
[91]	VERSTEIJNE E, VAN DAM J L, SUKER M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial[J]. J Clin Oncol, 2022, 40(11): 1220-1230. doi: 10.1200/JCO.21.02233
[92]	YAMAGUCHI J, YOKOYAMA Y, FUJⅡ T, et al. Results of a phase Ⅱ study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)[J]. Ann Surg, 2022, 275(6): 1043-1049. doi: 10.1097/SLA.0000000000005430
[93]	CANON J, REX K, SAIKI A Y, et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575(7781): 217-223. doi: 10.1038/s41586-019-1694-1
[94]	FELL J B, FISCHER J P, BAER B R, et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer[J]. J Med Chem, 2020, 63(13): 6679-6693. doi: 10.1021/acs.jmedchem.9b02052
[95]	KWAN A K, PIAZZA G A, KEETON A B, et al. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors[J]. J Exp Clin Cancer Res, 2022, 41(1): 27. doi: 10.1186/s13046-021-02225-w
[96]	KEMP S B, CHENG N, MARKOSYAN N, et al. Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer[J]. Cancer Discov, 2022: CD-22-1066.
[97]	MOKHTECH M, MICCIO J A, JOHUNG K, et al. Multiagent chemotherapy followed by stereotactic body radiotherapy versus conventional radiotherapy for resected pancreas cancer[J]. Am J Clin Oncol, 2022, 45(11): 450-457. doi: 10.1097/COC.0000000000000947
[98]	NAFFOUJE S A, SABESAN A, KIM D W, et al. Adjuvant chemoradiotherapy in resected pancreatic ductal adenocarcinoma: where does the benefit lie? A nomogram for risk stratification and patient selection[J]. J Gastrointest Surg, 2022, 26(2): 376-386. doi: 10.1007/s11605-021-05130-x
[99]	RUTENBERG M S, NICHOLS R C. Proton beam radiotherapy for pancreas cancer[J]. J Gastrointest Oncol, 2020, 11(1): 166-175. doi: 10.21037/jgo.2019.03.02 pmid: 32175120
[100]	KOBEISSI J M, SIMONE C B 2nd, LIN H B, et al. Proton therapy in the management of pancreatic cancer[J]. Cancers, 2022, 14(11): 2789. doi: 10.3390/cancers14112789
[101]	NAUMANN M, CZEMPIEL T, LÖßNER A J, et al. Combined systemic drug treatment with proton therapy: investigations on patient-derived organoids[J]. Cancers, 2022, 14(15): 3781. doi: 10.3390/cancers14153781
[102]	SELVANESAN B C, CHANDRA D, QUISPE-TINTAYA W, et al. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice[J]. Sci Transl Med, 2022, 14(637): eabc1600. doi: 10.1126/scitranslmed.abc1600
[103]	MARIN I, BOIX O, GARCIA-GARIJO A, et al. Cellular senescence is immunogenic and promotes anti-tumor immunity[J]. Cancer Discov, 2022: CD-22-0523.
[104]	HEWITT D B, NISSEN N, HATOUM H, et al. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (HyperAcute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer[J]. Ann Surg, 2022, 275(1): 45-53. doi: 10.1097/SLA.0000000000004669
[105]	ZHANG Z W, LIU X D, ZHOU L R, et al. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: a retrospective analysis of 302 Chinese patients[J]. Histol Histopathol, 2022, 37(10): 1031-1040.
[106]	MELIEF C J M. T-cell immunotherapy against mutant KRAS for pancreatic cancer[J]. N Engl J Med, 2022, 386(22): 2143-2144. doi: 10.1056/NEJMe2204283

2022年度胰腺癌研究及诊疗新进展

New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 106

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张会强, 江泽飞. 2022年改变晚期乳腺癌临床实践的重要研究[J]. 中国癌症杂志, 2023, 33(2): 110-116.
[2]	庄晗, 凌池芳, 王佳舟, 韩序, 姜睿, 胡伟刚. 局部晚期胰腺癌75 Gy同步加量放射治疗的剂量可行性研究[J]. 中国癌症杂志, 2023, 33(1): 54-60.
[3]	李语婕, 陈颢. 靶向TROP2在胰腺癌治疗中的潜力[J]. 中国癌症杂志, 2022, 32(3): 268-273.
[4]	吴梦吟, 吴春晓, 庞怡, 王春芳, 顾凯, 龚杨明, 鲍萍萍, 施亮, 窦剑明, 向詠梅, 施燕. 2016年上海市胰腺癌发病和死亡情况与2002—2016年流行趋势分析[J]. 中国癌症杂志, 2022, 32(2): 97-105.
[5]	罗国培, 虞先濬. 胰腺癌精准治疗：从小众走向主流[J]. 中国癌症杂志, 2022, 32(10): 960-970.
[6]	朱鑫哲, 李浩, 徐华祥, 罗国培, 虞先濬. 2021年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2022, 32(1): 1-12.
[7]	杨士鹏, 刘颖, 王馨悦, 杨洋, 全吉淑, 林贞花 . PKLR在胰腺癌中的表达水平及临床病理学意义[J]. 中国癌症杂志, 2021, 31(8): 704-713.
[8]	唐　榕, 施　思, 张　波, 徐　近, 王　巍, 虞先濬. 2020年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2021, 31(1): 1-10.
[9]	张晓萌 , 麻宁一 , 祝鸿程 , 艾沓杉 , 任志刚 . 胰腺癌术后辅助性放化疗的效果及预后因素分析[J]. 中国癌症杂志, 2020, 30(7): 519-524.
[10]	毛铁波, 崔玖洁, 王理伟. 从基础到临床：2019年胰腺癌研究进展[J]. 中国癌症杂志, 2020, 30(2): 81-89.
[11]	宁周雨, 花永强, 徐立涛, 庄丽萍, 冯兰云, 陈　颢, 王　鹏, 沈晔华, 林钧华, 陈　震, 孟志强. 白蛋白结合型紫杉醇联合吉西他滨动脉灌注治疗进展期胰腺癌的安全性和有效性回顾性研究[J]. 中国癌症杂志, 2020, 30(2): 128-134.
[12]	刘梦奇, 吉顺荣, 徐晓武, 虞先濬. 2019年胰腺癌研究及诊疗新进展[J]. 中国癌症杂志, 2020, 30(1): 1-10.
[13]	潘泽雁,湛先保 . 嵌合抗原受体T细胞治疗胰腺癌的现状及未来策略[J]. 中国癌症杂志, 2019, 29(7): 481-485.
[14]	朱序勤,贾淞淋,祁　洁,申雪芳,龙　江,缪长虹 . 影响胰腺癌根治术预后的围手术期相关因素的回顾性分析[J]. 中国癌症杂志, 2019, 29(7): 521-527.
[15]	吴小华，张　剑，尹如铁，娄　阁，高雨农. 优化卵巢癌Ⅰ期临床研究管理中国专家经验[J]. 中国癌症杂志, 2019, 29(5): 321-327.